N.A. TARASOVA, N.R. KHASANOV

 Kazan State Medical University, Kazan

Contact details:

Tarasova N.A. — post-graduate student of the Department of Propedeutics of Internal Diseases named after Prof. S.S. Zimnitskiy

Address: 49 Butlerov St., Kazan, Russian Federation, 420012, tel.: +7-987-262-03-06, e-mail: aleks37@yandex.ru

This review focuses on definition of iron deficiency (ID) in patients with cardiovascular diseases (CVD), pathophysiology of ID in coronary artery disease (CAD) and chronic heart failure (CHF). The currently studied effects of ID therapy in patients with CAD and CHF are highlighted. Most of the published studies demonstrate the negative impact of iron deficiency on the structure and function of the heart, quality of life and prognosis of patients with myocardial infarction (MI) and CHF. The effectiveness of ID correction in patients has been studied extensively, nevertheless there are ongoing studies on the evaluation of efficacy of various parenteral iron forms, as well as on their influence on long-term prognosis in patients with CHF. The correction of iron deficiency reduces the damage and necrosis size in patients with MI, improves left ventricular systolic function and exercise capacity after MI. At the same time, the available data on the ID correction in patients with CHF after myocardial infarction are insufficient and require further study.

Key words: iron deficiency, chronic heart failure, myocardial infarction, coronary artery disease.

REFERENCES

1. Rumyantsev G.A. et al. Prevalence of iron deficiency states and factors influencing it. Meditsinskiy sovet, 2015, no. 6, pp. 62–66 (in Russ.).
2. Jankowska E.A. et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J, 2010, no. 31, pp. 1872–1880.
3. Reinhold J. et al. Iron deficiency for prognosis in acute coronary syndrome — A systematic review and meta-analysis. Int J Cardiol, 2021, vol. 328, pp. 46–54.
4. Chronic heart failure. Clinical recommendations. Klinicheskie rekomendatsii. Rossiyskiy kardiologicheskiy zhurnal, 2020, no. 25 (11), p. 4083 (in Russ.).
5. Gil V.M., Ferreira J.S. Anemia and iron deficiency in heart failure. Rev Port Cardiol, 2014, vol. 33 (1), pp. 39–44.
6. Zhang H. et al. Myocardial Iron Deficiency and Mitochondrial Dysfunction in Advanced Heart Failure in Humans. J Am Heart Assoc, 2022, vol. 11 (11), p. e022853.
7. Leszek P. et al. Myocardial iron homeostasis in advanced chronic heart failure patients. Int J Cardiol, 2012, vol. 159 (1), pp. 47–52.
8. Alnuwaysir R.I.S. Iron Deficiency in Heart Failure: Mechanisms and Pathophysiology. J Clin Med, 2021, vol. 11 (1), p. 125.
9. Toblli J.E. Ferric carboxymaltose-mediated attenuation of Doxorubicin-induced cardiotoxicity in an iron deficiency rat model. Chemother Res Pract, 2014.
10. Wischmann P. et al. Safety and efficacy of iron supplementation after myocardial infarction in mice with moderate blood loss anaemia. ESC Heart Fail, 2021, vol. 8 (6), pp. 5445–5455.
11. Inserte J. et al. Implications of Iron Deficiency in STEMI Patients and in a Murine Model of Myocardial Infarction. JACC Basic Transl Sci, 2021, vol. 6 (7), pp. 567–580.
12. Elkammash A. et al. Iron Deficiency in Heart Failure: What Do We Know So Far? Cureus, 2022, vol. 14 (10), p. e30348.
13. Klip I.T. et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J, 2013, vol. 165, pp. 575–582.
14. Jankowska E.A. et al. Iron deficiency predict impaired exercise capacity in patients with systolic chronic heart failure. J Card Fail, 2011, vol. 17, pp. 899–906.
15. Anand I., Gupta P. How I treat anemia in heart failure. Blood, 2020, vol. 136 (7), pp. 790–800.
16. Ettinger O.A. et al. Anemia in patients with chronic heart failure: the role of iron deficiency and its correction. Consilium Medicum (in Russ.).
17. Anker S.D., Comin C.J., Filippatos G. et al. FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med, 2009, vol. 361 (25), pp. 2436–2448.
18. Okonko D.O. et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol, 2008, vol. 51 (2), pp. 103–112.
19. Ponikowski P., van Veldhuisen D.J., Comin-Colet J. et al. CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J, 2015, vol. 36 (11), pp. 657–668.
20. Van Veldhuisen D.J. et al. EFFECT-HF Investigators. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation, 2017, vol. 136 (15), pp. 1374–1383.
21. Beck-da-Silva L. et al. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. International Journal of Cardiology, 2013, vol. 168 (4), rr. 3439–3442.
22. Toblli J.E. et al. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol, 2007, vol. 50 (17), pp. 1657–1665.
23. Kalra P.R. et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet, 2022, vol. 400 (10369), pp. 2199–2209.
24. McDonagh T.A. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J, 2021, vol. 42 (36), pp. 3599–3726.
25. Meroño O. et al. Iron Deficiency in Patients with Acute Coronary Syndrome: Prevalence and Predisposing Factors. Rev Esp Cardiol (Engl Ed), 2016, vol. 69 (6), pp. 615–617.
26. Cosentino N. et al. Iron deficiency in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Int J Cardiol, 2020, vol. 300, pp. 14–19.
27. Meroño O. et al. Iron Deficiency Is a Determinant of Functional Capacity and Health-related Quality of Life 30 Days After an Acute Coronary Syndrome. Rev Esp Cardiol (Engl Ed), 2017, vol. 70 (5), pp. 363–370.
28. Zeller T. et al. Adverse Outcome Prediction of Iron Deficiency in Patients with Acute Coronary Syndrome. Biomolecules, 2018, vol. 8 (3), p. 60.
29. Silva C. et al. Prognostic impact of iron deficiency in acute coronary syndromes. Portuguese Journal of Cardiology, 2021, vol. 40, pp. 525–630.
30. Gürgöze M.T. et al. Relation of Iron Status to Prognosis After Acute Coronary Syndrome. Am J Cardiol, 2022, vol. 168, pp. 22–30.
31. Klinicheskie rekomendatsii “Ostryy koronarnyy sindrom bez pod»ema segmenta ST elektrokardiogrammy”. Assotsiatsiya serdechno-sosudistykh khirurgov Rossii. Obshcherossiyskaya obshchestvennaya organizatsiya “Rossiyskoe kardiologicheskoe obshchestvo” [Clinical guidelines «Acute coronary syndrome without raising the ST segment of the electrocardiogram.» Association of Cardiovascular Surgeons of Russia. All-Russian public organization «Russian Society of Cardiology»]. Moscow, 2020.
32. Weir R.A. et al. Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: prevalence, clinical characteristics, and prognostic importance. Am J Cardiol, 2006, vol. 97 (10A), pp. 13–25.
33. Jenča D. et al. Heart failure after myocardial infarction: incidence and predictors. ESC Heart Fail, 2021, vol. 8 (1), pp. 222–237.
34. Sulo G. et al. Heart failure complicating acute myocardial infarction; burden and timing of occurrence: a nation-wide analysis including 86 771 patients from the cardiovascular disease in Norway (CVDNOR) project. J Am Heart Assoc, 2016, vol. 5, p. e002667.
35. Agra Bermejo R. et al. Determinants and Prognostic Impact of Heart Failure and Left Ventricular Ejection Fraction in Acute Coronary Syndrome Settings. Rev Esp Cardiol (Engl Ed), 2018, vol. 71 (10), pp. 820–828.
36. Ponikowski P. et al. AFFIRM-AHF investigators. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet, 2020, vol. 396 (10266), pp. 1895–1904.